SP Angel Research Note

RNS Number : 7079F

N4 Pharma PLC

18 November 2020

 

18 November 2020

N4 Pharma plc

("N4 Pharma" or the "Company")

SP Angel Research Note

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to announce that its joint broker SP Angel Corporate Finance LLP has issued an initiation research report on the Company.

To view SP Angel's research note, please visit the Company's website:

https://www.n4pharma.com/investors/investor-information/

Enquiries:

N4 Pharma plc
Nigel Theobald, CEO	Via IFC Advisory
Luke Cairns, Executive Director
SP Angel Corporate Finance LLP	Tel: [phone]
Nominated Adviser and Joint Broker
Matthew Johnson/Caroline Rowe (Corporate Finance)
Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)
Turner Pope Investments (TPI) Limited	Tel: [phone]
Joint Broker
Andy Thacker
IFC Advisory Ltd Financial PR Graham Herring Zach Cohen	Tel: [phone]

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec®.

N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre-clinical and clinical programmes, N4 Pharma will seek to receive up-front payments, milestone payments and ultimately royalty payments once products reach the market.

 

END

 

 

MSCKVLBFBFLBFBK